Skip to main content Accessibility help
×
Home
  • Print publication year: 2016
  • Online publication date: March 2016

Chapter 26 - Lessons learned: symptomatic trials in early Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges
1.Dalaker, TO, Larsen, JP, Bergsland, N, et al. Brain atrophy and white matter hyperintesisites in early Parkisnon's disease. Mov Disord 2009; 24: 223341.
2.Jakobson, S, Linder, J, Forsgren, L, et al. Pre- and postsynaptic dopamine SPECT in early phase of idiopathic parkinsonism: a population-based study. Eur J Nucl Med Mol Imaging 2010; 37: 215464.
3.Laere, KV, Clerinx, K, D'Hondt, E, de Groot, T, Vandenberghe, W. Combine striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010; 51: 58895.
4.Evatt, ML, DeLong, MR, Kumari, M, et al. High prevalence of hypovitaminosis D status in patient with early Parkinson disease. Arch Neurol 2011; 68: 31419.
5.Shiraishi, M, Kobayashi, T, Watanabe, H, Kamo, , Hasegawa, Y. Serum somatostatin in early stage Parkinson's disease. Acta Neurol Scand 2010; 121: 2259.
6.Charles, PD, Dolhun, RM, Gill, CE, et al. Deep brain stimulation in early Parkinson's disease: Enrollment experience from a pilot trial. Parkinsonism Relat Disord 2012; 18: 26873.
7.Gill, CE, Allen, LA, Konrad, PE, et al. Deep brain stimulation of early-stage Parkinson's disease: an illustrative case. Neuromodulation 2011; 14: 51522.
8.Phillips, L, Litcofsky, KA, Pelster, M, et al. Subthalamic nucleus deep brain stimulation impacts language in early Parkinson's disease. PLoS One 2012; 7: e42829.
9.Kahn, E, D’Haese, PF, Dawant, B, et al. Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomized clinical trial. J Neurol Neurosurg Psychiatry 2012; 83: 16470.
10.Shill, HA, Obradov, S, Katsnelson, Y, Pizinger, R. A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease. Mov Disord 2011; 26: 147780.
11.Hauser, RA, Schapira, AHV, Rasciol, O, et al. Randomized double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25: 25429.
12.Schapira, AHV, Barone, P, Hauser, RA, et al. Patient reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advance Parkinson's disease. Eur J Neurol 2013; 20: 506.
13.Poewe, W, Rascol, O, Barone, P, et al. Extended-release pramipexole in early Parkinson disease. Neurology 2011; 75965.
14.Rascol, O, Barone, P, Hauser, RA, et al. Efficacy, safety and tolerability of overnight switching from immediate-to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord 2010; 25: 232632.
15.Parkinson Study Group CALM Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson's disease. Arch Neurol 2009; 66: 56370.
16.Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose parmipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord 2011; 26: 3744.
17.Hauser, RA, Reichmann, H, Lew, M, et al. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. International J Neurosci 2011; 121: 24653.
18.Watts, RL, Lyons, KE, Pahwa, R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010; 25: 85866.
19.Bronzova, J, Sampiao, C, Hauser, RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010; 25: 73846.
20.Sampiao, C, Bronzova, J, Hauser, RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large randomized double-blind trials. Mov Disord 2011; 26: 146476.
21.Shapira, AHV, Stocchi, F, Borgohain, R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 2013; 20: 27180.
22.Stocchi, F, Borgohain, R, Onofrj, M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 10612.
23.Simuni, T, Borushko, E, Avram, MJ, et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord 2010; 25: 28636.
24.Viallet, F, Pitel, S, Lancrenon, S, Blin, O. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Curr Med Res Opin 2013; 29: 2331.
25.Olanow, W, Hauser, RA, Jankovick, J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design and baseline characteristics. Mov Disord 2008; 23: 2194201.
26.Olanow, W, Rascol, O, Hauser, RA, et al. A double blind, delayed-start trial of rasagaline in Parkinson's disease. N Engl J Med 2009; 361: 126878.
27.Hauser, RA, Lew, MF, Hurtig, HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24: 56473.
28.Schenkman, M, Hall, D, Barón, AE, et al. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012; 92: 1395410.